Cargando…
Advancing Drug Innovation for Neglected Diseases—Criteria for Lead Progression
The current drug R&D pipeline for most neglected diseases remains weak, and unlikely to support registration of novel drug classes that meet desired target product profiles in the short term. This calls for sustained investment as well as greater emphasis in the risky upstream drug discovery. Ac...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727960/ https://www.ncbi.nlm.nih.gov/pubmed/19707561 http://dx.doi.org/10.1371/journal.pntd.0000440 |